TrialCurrent cancer drug targets2025

A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance.

Jing Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.